Yuhang Shang, Xuelian Wang, Yansong Liu, Weilun Cheng, Yunqiang Duan, Zhengbo Fang, Jiangwei Liu, Fanjing Kong, Ting Wang, Tianshui Yu, Anbang Hu, Jiarui Zhang, Hanyu Zhang, Mingcui Li, Zhiyuan Rong, Yanling Li, Suborna S Shakila, Xinxin Li, Jianyuan Feng, Fei Ma, Baoliang Guo
BACKGROUND: Guideline recommendations for the application of neoadjuvant chemotherapy (NACT) in T2N1M0 stage hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer are ambiguous. The debate continues regarding whether NACT or adjuvant chemotherapy (ACT) offers superior survival outcomes for these patients. MATERIALS AND METHODS: Female patients diagnosed with HR + /HER2- breast cancer at T2N1M0 stage between 2010 and 2020, were identified from the Surveillance, Epidemiology, and End Results database and divided into two groups, the NACT group and the ACT group...
April 21, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society